Conditions: Diabetes Mellitus
Allocation: RANDOMIZED | Intervention model: CROSSOVER
Enrollment: 16
Healthy volunteers: yes

Brief summary:
The purposes of this study are to determine the pharmacokinetics and pharmacodynamics of LY2963016 compared to those of basal insulin. The study will also gather information on the safety and tolerability of LY2963016 in healthy subjects. The study is approximately 12 weeks.

Detailed description:

Arms:
arm 1: A single 0.5-unit per kilogram (U/kg) dose of LY2963016 will be administered subcutaneously. arm 2: A single 0.5-U/kg dose of Lantus will be administered subcutaneously.

Interventions: intervention 1: LY2963016 intervention 2: Lantus
Intervention descriptions: intervention 1: Administered subcutaneously intervention 2: Administered subcutaneously

Protocol document: